laboratory crp of amer hldgs (LH) Key Developments
Laboratory Corp. of America Holdings Presents at Piper Jaffray Heartland Summit, Jun-23-2015
Jun 19 15
Laboratory Corp. of America Holdings Presents at Piper Jaffray Heartland Summit, Jun-23-2015 . Venue: Minneapolis, Minnesota, United States. Speakers: David P. King, Chairman and Chief Executive Officer.
Laboratory Corp. of America Seeks Acquisitions
Jun 9 15
Laboratory Corp. of America Holdings (NYSE:LH) is seeking acquisitions. Dave King, Chairman and Chief Executive Officer, said, "We have an undrawn revolver, we have good accumulation of cash, we do intend to continue to do the tuck-in and fold-in acquisitions that we've historically done, even through the delevering process."
LabCorp Expands Access to LabCorp AccuDraw to Support Better Patient Care
Jun 4 15
Laboratory Corporation of America Holdings announced the expanded availability of its proprietary specimen collection and handling software, LabCorpAccuDraw. Combining on-screen visual cues with step-by-step tutorials, AccuDraw is an innovative tool designed to guide the health care professional who collects patient specimens throughout the specimen collection process. AccuDrawhelps to facilitate collection and appropriate stabilization of the correct specimen type and sample volume. This technology-enabled solution leads to fewer errors in specimen collection and processing, a reduced chance of delays in testing, and a lower likelihood of having a patient undergo a second visit to a health care professional for further specimen collection. AccuDraw has been used in LabCorp's patient service centers and by LabCorp’s phlebotomists located in client locations for over five years. AccuDrawhas previously only been, and will continue to be, available to LabCorp clients through the LabCorp Beacon application. AccuDraw provides a detailed set of specimen collection and handling instructions, allowing office staff to spend more time on patient care and less time confirming the specimen collection process and requirements. On-screen visual cues are combined with detailed collection instructions to help ensure specimen and collection accuracy in the physician office. For patients and the physician office, AccuDraw provides: Improved precision and accuracy – Visual cues are customized to the specific physician test order and linked to LabCorp’s current test requirements. High-quality specimens – the guided process and clear instructions helps to ensure the quality specimen is sent to the laboratory for testing. Time efficiencies – Reduce the amount of time spent speaking to the lab about specimen requirements or identifying specimens that were not properly submitted to the lab. Reduction in repeat draws – AccuDraw’s collection, handling, and shipping guidance significantly reduces the need for patient redraws and repeat visits.
Sysmex Corp. and Laboratory Corp. of America Holdings Announce a Strategic Collaboration for Blood-Based Molecular Testing Services and Products
Jun 1 15
Sysmex Corp. and Laboratory Corp. of America Holdings announced a strategic collaboration focused on the development of blood-based molecular diagnostic tests to advance precision medicine in oncology. The collaboration combines Sysmex Inostics’ strength in the development of innovative blood-based diagnostic solutions with LabCorp's unparalleled capabilities: global leadership in precision medicine through Covance Drug Development’s (Covance) extensive involvement in oncology clinical trials and a unique ability to commercialize clinically-relevant diagnostic tests through LabCorp Diagnostics as such applications are developed. The Sysmex OncoBEAM™ and Plasma Sequencing assays allow for molecular genetic analysis of cell-free tumor DNA from blood samples. These technologies, often referred to as liquid biopsies, provide non-invasive alternatives to biopsies under specific circumstances and are designed to determine the mutational status of a patient’s tumor. These highly-sensitive methods allow for the potential selection of appropriate therapeutic agents and, in some cases, may eliminate the need for further surgeries or biopsies. Moreover, blood-based diagnostic DNA tests can be performed when no tumor tissue is available and utilized to serially monitor tumor changes in patients over time or in response to therapeutic treatment. The OncoBEAM™ assays target a wide variety of clinically actionable genetic mutations in cancer and, along with sequencing-based evaluation of circulating tumor DNA through Plasma Sequencing, offer biopharmaceutical companies powerful tools for developing new therapeutic options. Under the terms of this collaboration, Sysmex Inostics will provide reagents and, when appropriate, services to enable Covance’s central laboratory to perform OncoBEAM™ and Plasma Sequencing testing services in its global locations to support oncology clinical trials. In addition, as clinical utility of these technologies is further characterized through ongoing clinical trials, the parties will evaluate opportunities to develop commercial applications for Sysmex’s technologies in clinical diagnostics.
Laboratory Corporation of America Holdings Announces Full Portfolio of Hepatitis C Virus Drug Resistance Assays
May 18 15
Laboratory Corporation of America Holdings announced the launch of two new Hepatitis C Virus (HCV) drug resistance assays. The HCV NS5A and NS5B Drug Resistance Assays expand LabCorp's portfolio of HCV resistance tests that includes HCV GenoSure NS3/4A, which was launched in 2011. These tests are available through Monogram Biosciences, a member of the LabCorp Specialty Testing Group, and a leader in the development and commercialization of innovative antiviral diagnostics. Chronic viral hepatitis is the leading cause of liver failure, liver transplantation and hepatocellular carcinoma. The U.S. Centers for Disease Control and Prevention (CDC) estimates that more than three million people in the U.S., and 170 million individuals worldwide, are infected with HCV. Since 2011, the U.S. Food and Drug Administration (FDA) has approved six new drug applications for HCV treatment that include one or more direct acting antiviral (DAA) agents. DAA-based regimens have dramatically improved HCV cure rates compared to interferon-based treatment regimens, which have been standard of care for over two decades. Although DAA treatment is highly successful, DAA treatment can fail if a patient is infected with certain HCV variants that are drug resistant. LabCorp's HCV drug resistance assays provide clinicians with actionable knowledge that can guide treatment decisions. The HCV NS5B Drug Resistance Assay assesses resistance to sofosbuvir, which was approved as a single DAA in 2013 and as a co-formulation with the NS5A inhibitor, ledipasvir, in 2014. The HCV NS5A Drug Resistance Assay assesses resistance to ledipasvir. In addition, LabCorp's portfolio of HCV resistance assays can assess resistance to each component of the latest FDA-approved DAA-based regimen, which is comprised of paritaprevir, ombitasvir and dasabuvir. LabCorp's HCV DAA resistance assays are the first to be developed using next generation sequencing (NGS) technology, which features improved discrimination of small populations of drug resistant virus. The complete portfolio of LabCorp HCV drug resistance assays is also available through Monogram and for customers of Covance Drug Development to support pre-clinical development and clinical evaluation of new HCV DAA candidates.